Literature DB >> 8431519

Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures.

M Wolff1, W Jelkmann.   

Abstract

The effects of agents used in combination chemotherapy were studied on erythropoietin synthesis in cultures of the human hepatoma cell line, HepG2. Erythropoietin was measured by radioimmunoassay in the culture media after 24-h treatment periods. The RNA synthesis-inhibiting drugs daunorubicin, cyclophosphamide, ifosfamide, and cis-diamine-dichloroplatinum produced a dose-dependent decrease of the production of erythropoietin. Inhibition was also induced by the tubulin-binding agents vincristine and colchicine and the immunosuppressive agents azathioprine and cyclosporin A. The DNA synthesis-inhibiting drugs methotrexate and cytosine arabinoside, the antimycotics 5-fluorocytosine and amphotericin B, and glucocorticoids did not inhibit. Viability studies showed that the inhibition of erythropoietin production was partly correlated with cytotoxicity. These data could be relevant with respect to recombinant erythropoietin replacement therapy in tumor-associated anemia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431519     DOI: 10.1007/bf01737686

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  27 in total

1.  The regulated expression of erythropoietin by two human hepatoma cell lines.

Authors:  M A Goldberg; G A Glass; J M Cunningham; H F Bunn
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Recombinant human erythropoietin in the treatment of the anaemia of cancer.

Authors:  R I Abels
Journal:  Acta Haematol       Date:  1992       Impact factor: 2.195

3.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

4.  Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy.

Authors:  L Schapira; J H Antin; B J Ransil; K H Antman; J P Eder; C J McGarigle; M A Goldberg
Journal:  Blood       Date:  1990-12-01       Impact factor: 22.113

5.  Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration.

Authors:  W Oster; F Herrmann; H Gamm; G Zeile; A Lindemann; G Müller; T Brune; H P Kraemer; R Mertelsmann
Journal:  J Clin Oncol       Date:  1990-06       Impact factor: 44.544

6.  Anemia induces accumulation of erythropoietin mRNA in the kidney and liver.

Authors:  M C Bondurant; M J Koury
Journal:  Mol Cell Biol       Date:  1986-07       Impact factor: 4.272

7.  Erythropoietin treatment of anemia associated with multiple myeloma.

Authors:  H Ludwig; E Fritz; H Kotzmann; P Höcker; H Gisslinger; U Barnas
Journal:  N Engl J Med       Date:  1990-06-14       Impact factor: 91.245

8.  Mechanisms of abnormal erythropoiesis in malignancy.

Authors:  N Dainiak; V Kulkarni; D Howard; M Kalmanti; M C Dewey; R Hoffman
Journal:  Cancer       Date:  1983-03-15       Impact factor: 6.860

9.  In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction.

Authors:  J Fandrey; H F Bunn
Journal:  Blood       Date:  1993-02-01       Impact factor: 22.113

10.  Serum immunoreactive erythropoietin in children with acute leukaemia at various stages of disease--and the effects of treatment.

Authors:  M Hellebostad; J Marstrander; S H Slørdahl; P M Cotes; H E Refsum
Journal:  Eur J Haematol       Date:  1990-03       Impact factor: 2.997

View more
  6 in total

1.  Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.

Authors:  R Canaparo; F Casale; E Muntoni; G P Zara; C Della Pepa; E Berno; N Pons; G Fornari; M Eandi
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Interleukin 1 beta and phorbol ester induce tumour necrosis factor alpha production in a hepatic cell line (HepG2).

Authors:  S Frede; J Fandrey; W Jelkmann
Journal:  Pflugers Arch       Date:  1996-04       Impact factor: 3.657

3.  Evidence against a major role for Ca2+ in hypoxia-induced gene expression in human hepatoma cells (Hep3B).

Authors:  E Metzen; J Fandrey; W Jelkmann
Journal:  J Physiol       Date:  1999-06-15       Impact factor: 5.182

4.  Nitric oxide donors suppress erythropoietin production in vitro.

Authors:  W Schobersberger; G Hoffmann; J Fandrey
Journal:  Pflugers Arch       Date:  1996-10       Impact factor: 3.657

Review 5.  Inadequate erythropoietin response to anemia: definition and clinical relevance.

Authors:  G Barosi
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

6.  Role of hydrogen peroxide in hypoxia-induced erythropoietin production.

Authors:  J Fandrey; S Frede; W Jelkmann
Journal:  Biochem J       Date:  1994-10-15       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.